Nxera Pharma Co., Ltd. (FRA:JSS)

Market Cap	428.18M
Revenue (ttm)	165.29M
Net Income (ttm)	-35.38M
Shares Out	n/a
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6
Open	4.640
Previous Close	4.780
Day's Range	4.640 - 4.640
52-Week Range	4.040 - 6.300
Beta	n/a
RSI	51.44
Earnings Date	Feb 13, 2026

About Nxera Pharma

Nxera Pharma Co., Ltd. develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The company develops NBI-1117568, a muscarinic M4 agonist in phase 2 trial for schizophrenia and other neuropsychiatric disorders; and ORX750, an OX2 agonist i...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 374
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: JSS

Financial Performance

In 2024, Nxera Pharma's revenue was 28.84 billion, an increase of 125.87% compared to the previous year's 12.77 billion. Losses were -4.84 billion, -32.74% less than in 2023.

Financial numbers in JPY